Camurus AB (publ) (STO:CAMX)
Sweden · Delayed Price · Currency is SEK 503.00
-3.00 (-0.59%)
At close: Feb 27, 2026
Camurus AB Revenue
In the year 2025, Camurus AB had annual revenue of 2.27B SEK with 21.30% growth. Camurus AB had revenue of 464.46M in the quarter ending December 31, 2025, a decrease of -16.03%.
Revenue
2.27B
Revenue Growth
+21.30%
P/S Ratio
13.25
Revenue / Employee
7.95M
Employees
285
Market Cap
30.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.27B | 397.80M | 21.30% |
| Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
| Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
| Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
| Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioArctic AB | 2.00B |
| Saniona AB | 743.21M |
| Cantargia AB | 316.70M |
| BioInvent International AB | 244.85M |
| Hansa Biopharma AB | 222.27M |
| Genovis AB (publ.) | 129.65M |
| Egetis Therapeutics AB | 55.40M |
| Vicore Pharma Holding AB | 8.50M |
Camurus AB News
- 15 days ago - Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Camurus reports positive topline results for CAM2056, semaglutide monthly depot - PRNewsWire
- 4 months ago - Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 9 months ago - Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients - PRNewsWire
- 9 months ago - Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins - PRNewsWire
- 11 months ago - CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU - PRNewsWire
- 1 year ago - US FDA declines to approve Camurus' rare hormone disorder drug - Reuters
- 1 year ago - New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl - PRNewsWire